14C Isotope Labeling

Isotopically labeled materials to support your pathway to the clinic from Arcinova, A Quotient Sciences Company.

About our 14C radiolabeling services

What is 14C isotope radiolabeling?

Human ADME studies provide data for mass balance, pharmacokinetics, and metabolite characterization. This allows detailed understanding of the metabolism of a drug candidate to support regulatory submission.

A synthesis of the drug candidate is designed that uses a radioactive starting material to introduce one or more 14C atoms into the final structure. The labeling position is chosen to maximize the metabolic data that can be determined and builds upon hundreds of years of experience in designing short and economical routes ensuring high velocity of material delivery. The material produced has the same pharmacokinetic and metabolic properties as the unlabeled compound, but the presence of the radioactive element allows quantification of the parameters being studied.

What is stable isotope labeling (SIL)?

Mass spectrometry is the workhorse of bioanalysis, with millions of samples being analyzed daily across the world. Accurate quantification of the test substance is key and is accomplished using an internal standard. SIL materials provide ideal internal standards for studying development candidates.

A copy of the molecule is produced containing SIL atoms. These are not radioactive but can be distinguished from the unlabeled material by mass spectrometry, enhancing the accuracy of the measurements made.

Radiolabeling services from Arcinova, A Quotient Sciences Company can be combined into an integrated human ADME study with Quotient Sciences. For details on isotope labeling and ADME studies:

Ask the experts
Meet Iain Shaw, Senior Director of 14C Enabled Drug Development